Manufacturability and regulatory compliance are key barriers in the path of bringing a product from the laboratory to a regulated market. These considerations impact product and process design; they can accelerate innovation if incorporated early in research.
BTI has a suite of integrated capabilities, collaborative expertise, and a network of industry partners to support product innovation. With the ability to manufacture novel products at preclinical scales, BTI is well-equipped to establish technology readiness before commercialisation. Target products include antibodies, exosomes, gene therapy, cell therapy, and alternative proteins for food.
Visit the following webpages for more information: